Ultrafast Synthesizing Bismuth Mesoporous Nanolitchi Radiosensitizer Loading High Dose DOX for CT-Guided Enhanced Chemoradiotherapy

ACS Appl Mater Interfaces. 2019 Nov 20;11(46):42932-42942. doi: 10.1021/acsami.9b13647. Epub 2019 Oct 17.

Abstract

Radiotherapy and chemotherapy are both common clinical treatment methods. The combination of the two treatments can decrease tumor recurrence. In this study, bismuth-based mesoporous litchi-shaped Na0.2Bi0.8O0.35F1.91:20%Yb (NBOF) nanoparticles (NPs) have been reported as a radiosensitizer and as a nanovehicle for loading and slow-releasing doxorubicin (DOX). After assembling with amphiphilic poly(ethylene glycol) (PEG), NBOF-DOX-PEG qualified with excellent aqueous dispersibility and the enhanced tumor radiation and chemo-synergistic therapy characteristics. The formation of NBOF revealed the oxygen element in NBOF came from H2O and air in the synthesis and post-treatment process, and the size of NBOF could be adjusted by changing the concentration of doped Yb ion. The average size of NBOF was ca. 80 nm. Brunauer-Emmett-Teller results demonstrated the mesoporous structure of NBOF. So DOX could be loaded in NBOF and the optimized loading content was 39%. Then, NBOF-PEG exhibited a strong computed tomography signal whitening ability and enhanced radiotherapy effect. Combined with the chemotherapy ability of DOX, NBOF-DOX-PEG NPs presented remarkable synergistic tumor elimination ability. Meanwhile, NBOF-DOX-PEG NPs qualified for excellent biosafety. Our study not only proved the combined chemo- and radiotherapy for enhancing therapeutic effect but also supplied a functional Bi-based mesoporous nanovehicle for constructing an intelligent theranostic platform.

Keywords: CT imaging; bismuth; chemoradiotherapy; mesoporous structure; radiosensitizer; synergistic therapy.

MeSH terms

  • Animals
  • Bismuth* / chemistry
  • Bismuth* / pharmacology
  • Cell Line, Tumor
  • Chemoradiotherapy*
  • Doxorubicin* / chemistry
  • Doxorubicin* / pharmacology
  • Drug Carriers* / chemistry
  • Drug Carriers* / pharmacology
  • Female
  • Mammary Neoplasms, Experimental* / diagnostic imaging
  • Mammary Neoplasms, Experimental* / metabolism
  • Mammary Neoplasms, Experimental* / pathology
  • Mammary Neoplasms, Experimental* / therapy
  • Mice
  • Mice, Inbred BALB C
  • Nanostructures* / chemistry
  • Nanostructures* / therapeutic use
  • Porosity
  • Radiation-Sensitizing Agents* / chemistry
  • Radiation-Sensitizing Agents* / pharmacology
  • Tomography, X-Ray Computed*

Substances

  • Drug Carriers
  • Radiation-Sensitizing Agents
  • Doxorubicin
  • Bismuth